Regeneron Pharmaceuticals, Inc. (REGN) — Stock Price, Chart & Analysis
Regeneron Pharmaceuticals, Inc. (REGN) is a Healthcare stock currently trading at $784.36, up 1.59% on the day. It carries a market capitalization of $80.75B and a trailing P/E ratio of 19.12. Over the past 52 weeks, REGN has traded between $541.00 and $821.11. Regeneron Pharmaceuticals, Inc. pays a dividend yielding 0.5%. View the live REGN chart, technical opinion, analyst ratings, fundamentals and latest news below.
Regeneron Pharmaceuticals, Inc. (REGN) key data
| Price | $784.36 |
| Change (today) | +1.59% |
| Previous close | $772.11 |
| Market cap | $80.75B |
| P/E ratio (TTM) | 19.12 |
| EPS (TTM) | $41.02 |
| Dividend yield | 0.5% |
| 52-week high | $821.11 |
| 52-week low | $541.00 |
| Beta | 0.19 |
| Avg. volume | 1.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Regeneron Pharmaceuticals, Inc. (REGN)
How much does one share of Regeneron Pharmaceuticals, Inc. cost?
As of the latest update, one share of Regeneron Pharmaceuticals, Inc. (REGN) trades at $784.36 (+1.59% today).
What is Regeneron Pharmaceuticals, Inc.'s market cap?
Regeneron Pharmaceuticals, Inc. has a market capitalization of approximately $80.75B.
What is Regeneron Pharmaceuticals, Inc.'s P/E ratio?
Regeneron Pharmaceuticals, Inc. has a trailing price-to-earnings (P/E) ratio of 19.12.
What is Regeneron Pharmaceuticals, Inc.'s earnings per share (EPS)?
Regeneron Pharmaceuticals, Inc.'s trailing twelve-month EPS is $41.02.
Does Regeneron Pharmaceuticals, Inc. pay a dividend?
Yes — Regeneron Pharmaceuticals, Inc. pays a dividend with a yield of 0.5% ($3.76 per share annually).
What is Regeneron Pharmaceuticals, Inc.'s 52-week trading range?
Over the past year, REGN has traded between $541.00 and $821.11.
What is the analyst price target for Regeneron Pharmaceuticals, Inc.?
The mean analyst price target for Regeneron Pharmaceuticals, Inc. is $833.54. This is informational only and not investment advice.
Latest Regeneron Pharmaceuticals, Inc. (REGN) news
- NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron RevenuesNews · Aug 7, 2026
- CytomX Therapeutics Q2 Earnings Call HighlightsNews · Aug 7, 2026
- CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business UpdateNews · Aug 6, 2026
- Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ...News · Aug 6, 2026
- Surging Earnings Estimates Signal Upside for Regeneron (REGN) StockNews · Aug 5, 2026
- Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/YNews · Aug 5, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live REGN dashboard…